GSK warns Advair generic competition may affect business in 2017; Lilly plans to meet FDA about baricitinib; FDA warns companies selling 'illegal' products
Opdivo/Yervoy combination shows improved survival for melanoma patients in trial; global immunotherapy market likely to reach $75 billion by 2022; Mylan expands EpiPen recall
Lilly to invest $850 million in the U.S.; President Trump gives GOP leaders ultimatum on healthcare bill; Pfizer, Merck KGaA receive FDA approval for Bavencio
GOP unveils ACA replacement; Trump is working on new drug-pricing system; researchers to study thousands of immunotherapies
GSK files for FDA approval of shingles vaccine; Chinese drugmaker reportedly files for largest IPO since 2013; Sunovion completes deal to buy Cynapsus
Roche gets FDA approval for immunotherapy Tecentriq; insurers are sued for discrimination; the FDA proposes yanking generic ADHD drugs from market
FDA leader says drugmakers should develop more novel drugs; Merck to acquire Afferent for $1.25 billion; Colombia demands lower prices for Gleevec
Manufacturers team up to study drug combinations, a strategy expected to advance the category.
Bristol-Myers Squibb considered immunotherapy market leader; McKesson buys two cancer-care companies; Bayer names new CEO
The biotech company is working with the foundation and Brown University to develop new regimens for the socially stigmatized condition.
- Five things for pharma marketers to know: Monday, April 24, 2017
- Five things for pharma marketers to know: Tuesday, April 25, 2017
- Drugmakers battle for slice of Humira's billions
- Five things for pharma marketers to know: Wednesday, April 26, 2017
- Five things for pharma marketers to know: Thursday, April 27, 2017
MM&M honors 40 upstarts and veteran innovation gurus.
For the first time MM&M honors a group of 10 agency execs.